[go: up one dir, main page]

ES2192810T3 - Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis. - Google Patents

Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis.

Info

Publication number
ES2192810T3
ES2192810T3 ES99106438T ES99106438T ES2192810T3 ES 2192810 T3 ES2192810 T3 ES 2192810T3 ES 99106438 T ES99106438 T ES 99106438T ES 99106438 T ES99106438 T ES 99106438T ES 2192810 T3 ES2192810 T3 ES 2192810T3
Authority
ES
Spain
Prior art keywords
thermogenesis
monoxidine
employment
medicinal
stimulating activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99106438T
Other languages
English (en)
Inventor
Gareth Prof Dr Williams
Chen Dr Bing
Elbert Dr Kaan
Dieter Dr Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2192810T3 publication Critical patent/ES2192810T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE LA UTILIZACION DE MOXONIDINA Y SUS SALES DE ADICION DE ACIDO FISIOLOGICAMENTE ACEPTABLES PARA LA PRODUCCION DE PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO Y/O PREVENCION DE ALTERACIONES DE LA TERMOGENESIS, Y PARA ESTIMULAR LA TERMOGENESIS EN PERSONAS CON TRANSFORMACION DE ENERGIA ANORMALMENTE BAJA Y/O PERSONAS CON LA TERMOGENESIS DISMINUIDA DURANTE O AL FINAL DE UNA DIETA DE ADELGAZAMIENTO.
ES99106438T 1998-04-06 1999-03-29 Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis. Expired - Lifetime ES2192810T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19815411A DE19815411A1 (de) 1998-04-06 1998-04-06 Thermogenese stimulierend wirksame Arzneimittel

Publications (1)

Publication Number Publication Date
ES2192810T3 true ES2192810T3 (es) 2003-10-16

Family

ID=7863781

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99106438T Expired - Lifetime ES2192810T3 (es) 1998-04-06 1999-03-29 Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis.

Country Status (6)

Country Link
US (1) US6069147A (es)
EP (1) EP0951907B1 (es)
JP (1) JPH11322607A (es)
CA (1) CA2268213C (es)
DE (2) DE19815411A1 (es)
ES (1) ES2192810T3 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849992B1 (fr) * 2003-01-17 2007-03-16 Inst Phytoceutic Composition pour une administration par voie orale contenant des capsaicinoides
JP2009528999A (ja) * 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
WO2008066845A2 (en) * 2006-11-28 2008-06-05 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with norfluoxetine
US20090036426A1 (en) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
EP0812197A2 (en) * 1995-02-28 1997-12-17 Beiersdorf-Lilly GmbH Use of moxonidine for the treatment of atherosclerosis
HUP0003885A2 (hu) * 1996-06-06 2001-04-28 Eli Lilly And Co. Készítmény pangásos szívelégtelenség kezelésére

Also Published As

Publication number Publication date
US6069147A (en) 2000-05-30
CA2268213A1 (en) 1999-10-06
EP0951907B1 (de) 2003-03-05
DE59904415D1 (de) 2003-04-10
CA2268213C (en) 2008-01-29
DE19815411A1 (de) 1999-10-07
JPH11322607A (ja) 1999-11-24
EP0951907A1 (de) 1999-10-27

Similar Documents

Publication Publication Date Title
El Zawahry et al. Use of aloe in treating leg ulcers and dermatoses.
DE59504241D1 (de) Kombinationspräparat zur förderung des haarwachstums und ggf. des haut- und nagelwachstums sowie zur verhinderung bzw. zur beseitigung von haarausfall
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
ES2192810T3 (es) Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis.
DE122009000073I1 (de) Arzneimittel zur behandlung von viralen haut- und tumorerkrankungen
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
DK1343472T3 (da) Thixotropisk næsespray
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
HUP0200145A2 (hu) Tianeptin alkalmazása neurodegeneratív betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
IT1274699B (it) Estratto vegetale contro le ustioni
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
HUP0402624A2 (hu) Vírusgátlás n-dokozanollal
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
Wantke et al. Topical podophyllotoxin in psoriasis vulgaris
Maeng et al. Pediatric onychomycosis treated with oral antifungal drugs
SE9904863D0 (sv) New use
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
Strydom In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire